Sector Update

## FMCG

BSE Sensex: 9,149
S\&P CNX: 2,784
3 February 2009

COMPANY NAME
(Neutral, Rs769)
Britannia Industries
(Buy, Rs 1,382)

Colgate Palmolive
(Buy, Rs417)

Dabur India
(Neutral, Rs88)

GlaxoSmithKline Consumer
(Buy, Rs600)

Godrej Consumer Products
(Buy, Rs130)
Hindustan Unilever
(Neutral, Rs264)
ITC
(Buy, Rs181)

Marico
(Buy, Rs58)

Tata Tea

United Spirits
(Buy, Rs560)

Slowdown in volume growth apparent now: Our concerns on the likely decline in volume growth were reflected in the 3QFY09 results with major players like HUL, Marico, and Asian Paints facing severe pressure on volumes. Discretionary spends like paints, refined edible oil, deodorants and health supplements reported lower volume growth. High penetration categories like soaps and detergents reported flat volumes due to sharp price increases and grammage reduction. However, category focused players like Britannia, Colgate, and United Spirits reported sequential improvement in volume growth.

Benefit of lower crude based input price to reflect in 4QFY09: Our FMCG universe posted gross margin decline of 390bp YoY. Gross margins of large size declined just 220bp, while mid-size and small-size companies reported a gross margin decline of 830 bp and 550 bp respectively. Sharp decline in gross margin came as a surprise as we were expecting gross margin pressures to recede in the December quarter, particularly for companies using more of crude-based inputs. Inventories/forward covers of high cost raw materials purchased up to August/September resulted in severe margin erosion. We expect lower costs to start getting reflected in financials of 4 QFY 09 for users of crude-based inputs. We expect agri inputs to remain firm, which will delay margin recovery for user segments.

Lower ad spend and other expenditure restrict EBITDA margin decline: Despite the 390bp decline in gross margin, our FMCG universe companies were successful in restricting a decline in EBITDA margin to 170bp (operating leverage of 220bp) by focusing on cost control measures in ad spend and other overheads. Advertising spend for the companies (excluding ITC and Asian Paints) grew by a mere 2\% YoY in December 2008 ( $9.9 \%$ of sales in December $2008 \mathrm{v} / \mathrm{s} 11.4 \%$ in December 2007) v/s $12 \%$ YoY growth in September 2008. Fewer consumer activation initiatives and new launches contributed to lower ad spends. Lower growth in other expenditure also resulted in a positive operating leverage.

Large size companies outperform at operating level: Mid size companies were outperforming at the operating level till September 2008. Poor performance from Asian Paints and United Spirits resulted in 34\% PAT decline for mid size as against $9.3 \%$ increase for large caps and $10.3 \%$ PAT growth for small size. Large size companies in our coverage

CHANGE IN ESTIMATES

|  | FY09/CY08 |  |  |  |  | FY10/CY09 |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | NEW EPS EST | \% CHG. | YOY GR. (\%) | NEW EPS EST | \% CHG. | YOY GR. (\%) |  |  |
| Asian Paints | 39.1 | -21.6 | -10.2 |  | 46.7 | -19.1 | 19.6 |  |
| United Spirits | 33.7 | -29.2 | 0.0 |  | 47.5 | -29.7 | 40.9 |  |
| Godrej Consumer | 6.2 | -12.5 | -11.9 |  | 8.3 | -11.1 | 33.1 |  |
| GSK Consumer | 44.8 | 4.1 | 15.8 |  | 53.9 | 1.9 | 20.4 |  |

universe outperformed others at the operating profit level with EBITDA growing by $16 \%$ as against decline of $1.6 \%$ for small size and $27.1 \%$ for mid caps. EBITDA margin erosion for mid size was the highest at 639 bp as against a decline of 240 bp in small size and expansion of 44bp in large size.

Slackening volume growth a concern; margins set to expand; maintain selective approach: Although long term growth prospects for FMCG companies continue to remain positive, the short term outlook remains uncertain given the sluggish volume growth. We believe companies would pass on the benefit of lower raw material prices to revive the volume growth through sales promotion, offers and discounts. We believe initiatives taken by the companies to boost volume growth would restrict sharp expansion in operating margins. We are already witnessing price corrections/ promotions in toilet soaps and detergents; the trend is expected to catch up in a few more product categories. We continue to remain selective in our approach with bias towards companies with presence in categories with high consumer switching costs, strong pricing power and high entry barriers. Our top picks are: ITC in large size, Nestle in mid size and Marico in small size.

FMCG COMPANIES: SUMMARIZED PERFORMANCE (RS M)

|  | SALES |  |  | EBITDA |  |  | EBITDA MARGIN (\%) |  |  | PAT |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | DEC-07 | DEC-08 | CHG (\%) | DEC-07 | DEC-08 | CHG (\%) | DEC-07 | DEC-08 | CHG (BP) | DEC-07 | DEC-08 | CHG (\%) |
| Large size |  |  |  |  |  |  |  |  |  |  |  |  |
| Hind. Unilever | 36,874 | 43,077 | 16.8 | 5,642 | 6,931 | 22.8 | 15.3 | 16.1 | 79 | 5,540 | 6,101 | 10.1 |
| ITC | 34,580 | 38,333 | 10.9 | 11,997 | 13,527 | 12.8 | 34.7 | 35.3 | 59 | 8,307 | 9,032 | 8.7 |
| Total | 71,454 | 81,410 | 13.9 | 17,639 | 20,458 | 16.0 | 24.7 | 25.1 | 44 | 13,847 | 15,133 | 9.3 |
| Mid size |  |  |  |  |  |  |  |  |  |  |  |  |
| Asian Paints | 11,776 | 13,210 | 12.2 | 1,856 | 1,093 | -41.1 | 15.8 | 8.3 | -748 | 1,189 | 596 | -49.8 |
| United Spirits | 8,890 | 10,293 | 15.8 | 1,708 | 1,063 | -37.8 | 19.2 | 10.3 | -888 | 882 | 306 | -65.3 |
| Dabur | 6,497 | 7,787 | 19.9 | 1,163 | 1,290 | 10.9 | 17.9 | 16.6 | -134 | 945 | 1,085 | 14.8 |
| Total | 27,163 | 31,289 | 15.2 | 4,727 | 3,446 | -27.1 | 17.4 | 11.0 | -639 | 3,015 | 1,987 | -34.1 |
| Small size |  |  |  |  |  |  |  |  |  |  |  |  |
| Colgate | 3,675 | 4,192 | 14.1 | 611 | 746 | 22.0 | 16.6 | 17.8 | 116 | 605 | 777 | 28.6 |
| Britannia | 6,564 | 8,183 | 24.7 | 588 | 656 | 11.6 | 9.0 | 8.0 | -94 | 488 | 526 | 7.7 |
| Godrej Consumer | 2,728 | 3,421 | 25.4 | 568 | 483 | -15.0 | 20.8 | 14.1 | -671 | 430 | 401 | -6.9 |
| GSK Consumer | 2,841 | 3,334 | 17.3 | 357 | 402 | 12.7 | 12.6 | 12.1 | -50 | 275 | 326 | 18.5 |
| Marico | 5,062 | 6,228 | 23.0 | 643 | 791 | 23.2 | 12.7 | 12.7 | 2 | 428 | 509 | 19.0 |
| Tata Tea | 11,849 | 13,009 | 9.8 | 2,112 | 1,722 | -18.4 | 17.8 | 13.2 | -458 | 821 | 821 | -0.1 |
| Total | 32,719 | 38,367 | 17.3 | 4,879 | 4,801 | -1.6 | 14.9 | 12.5 | -240 | 3,047 | 3,359 | 10.3 |
| Grand Total | 131,336 | 151,066 | 15.0 | 27,245 | 28,705 | 5.4 | 20.7 | 19.0 | -174 | 19,909 | 20,479 | 2.9 |

Asian Paints reported steep decline in sales from $30.2 \%$ in 2QFY09 to $\mathbf{1 2 . 2 \%}$ in 3QFY09

EBITDA margin of United Spirits, Asian Paints, and Godrej Consumer declined by more than 650bp

## Large size companies EBITDA

 increased by $16 \%$ as against $27 \%$ decline in mid size and $1.6 \%$ decline in small size|  |  | GRoss margins | EBITDA MARGINS | operating leverage |
| :---: | :---: | :---: | :---: | :---: |
|  |  | CHg (BPS) | CHG (BPS) | CHg (BPS) |
| Gross margins declined 394bp for companies under MOSL universe | Large size |  |  |  |
|  | HUL | -233 | 79 | 312 |
|  | TTC | -161 | 59 | 220 |
|  | Total | -217 | 44 | 261 |
|  | Large size |  |  |  |
|  | Asian Paints | -520 | -748 | -228 |
|  | United Spirits | -964 | -888 | 76 |
|  | Dabur | -443 | -133 | 309 |
|  | Total | -832 | -639 | 194 |
| Colgate, HUL and ITC reported margin expansion due to operating leverage | Small size |  |  |  |
|  | Colgate | -377 | 116 | 493 |
|  | Britannia | -290 | -94 | 197 |
|  | Godrej Con | -1,374 | -671 | 703 |
|  | GSK Con | -44 | -50 | -6 |
|  | Marico | -214 | 2 | 216 |
|  | Tata Tea | -649 | -458 | 191 |
|  | Total | -554 | -240 | 315 |
|  | Grand Total | -394 | -174 | 220 |
|  |  |  |  | Source: Company/MO |



## Fewer product launches lead to lower ad spends

December 2008 witnessed fewer New Product Development (NPD) vis-à-vis the last quarter. Uncertain outlook due to slow down in the economy would be the key reason for the same. Notable launches during the quarter included Vivel Ultrapro by ITC (competing against Head and Shoulders and Clinic All Clear) and Saffola Zest, Saffola's brand extension to the snacks market (Category size Rs 30bn, 25\% CAGR). HUL launched new range of Dove deodorants, while GSK consumer launched ActivGrow targeting 2-6 year olds.

New launches squeezed out


Source: MOSL

| Volume growth | DEC-08 | DEC-07 | SEP-08 | QOQ TREND |
| :---: | :---: | :---: | :---: | :---: |
| Hindustan Unilever | 2.3 | 8.4 | 6.8 | $\downarrow$ |
| ITC (cigarette) | -3.5 | -1.0 | -2.0 | $\downarrow$ |
| Asian Paints | 2.0 | 27.0 | 19.0 | $\downarrow$ |
| United Spirits | 19.0 | 13.6 | 15.0 | $\uparrow$ |
| Colgate | 14.0 | 8.0 | 11.1 | $\uparrow$ |
| GSK Consumer | 13.0 | 2.0 | 16.0 | $\downarrow$ |
| Marico |  |  |  |  |
| Parachute | 9.0 | 8.0 | 12.0 | $\downarrow$ |
| Hair Oil | 14.0 | NA | 14.0 | $\longleftrightarrow$ |
| Saffola | 3.0 | 19.0 | 9.0 | $\downarrow$ |
| Godrej Consumer |  |  |  |  |
| Soaps | 19.0 | 9.0 | 14.0 | $\uparrow$ |
| Hair Color | 7.0 | 6.0 | -4.0 | $\uparrow$ |
| Dabur | 14.0 | NA | 13.0 | $\uparrow$ |

KEY RAW MATERIALS: PRICE TREND



COPRA PRICES (RS/QTL) - PRICES TO DECLINE FURTHER IN MARCH-08


SMP PRICES (RS/KG) - SHARP DECLINE FROM PEAK


## Top-2 Buys

## ITC Ltd

Adverse regulatory environment in cigarettes is near its peak (only pictorial warnings implementation left); $18 \%$ PBIT growth in 3QFY09 has been encouraging. Demand resilience and high entry barriers will ensure steady double digit profit growth.

* Poor performance from Hotels business is priced in. $2.5 \%$ market share in toilet soaps and rising consumer acceptability in skin care is positive due to $20-25 \%$ EBIDTA margin and market size of more than US $\$ 2 b$.
* Our revised estimates for FY09 and FY10 are Rs8.7 (v/s Rs9) and Rs10.2 (v/s Rs10.4) respectively. The stock trades at 20.8x FY09E EPS of Rs8.7 and 17.8x FY10E EPS of Rs10.2.


## Nestle India

* Nestle India is best placed to ride on the expected growth in processed foods market due to strong technology of parent and focus on processed foods.
- Input cost pressures are expected to sustain in the near term due to strong prices of sugar and steady trend in liquid milk ( $45 \%$ of input cost), but dominant market share and strong brands will prevent margin erosion for the company.
* We expect Nestle to sustain double digit volume growth and $25 \%$ PAT growth for CY07-10. The stock trades at attractive valuations of 26.3 xFY 09 and 20.6 xFY 10 earnings.


## Top-2 Switches

## Hindustan Unilever

\& HUL volume growth has declined from $6.8 \%$ in 3 QCY 08 to $2.3 \%$ in 4QCY08 due to lower consumer off-take resulting from sharp increase in prices and grammage reduction in key brands. We expect coming 12 months volume growth to decline from $7 \%$ to $4.5 \%$.
\& HUL has lost market share across product categories (except detergents). We are concerned with 470bp market share loss in toilet soaps in past 12 months.
$\&$ We expect increase in sales promotions and price reduction across categories. We expect $16.7 \%$ PAT growth in FY10 (comparable quarters), which makes the stock fairly priced at 23.6x FY10 EPS of Rs11.2.

## Asian Paints

\& Asian Paints has seen sharp deacceleration in volume growth from 19\% in 2QFY09 to flat volumes in 3QFY09 due to dealer destocking and poor Diwali sales. Fresh painting ( $20 \%$ of sales) would get impacted by the slowdown in real estate, while repainting (being a discreationary spend) would get postponed under the current environment.
\& Although we expect profit margins to increase on QoQ basis, high cost material inventory, increase in overheads due to capacity expansions and lower volume growth will ensure that EBIDTA margin would not reach FY08 level of $14.5 \%$ in the medium term.
\& The stock trades at $19.7 \times$ FY09E and $16.5 x$ FY10E.

COMPARATIVE VALUATION

|  | CMP <br> (RS) | RECO | T.P. <br> (RS) | UPSIDE <br> (\%) | EPS (RS) |  | P/E (X) |  | EV/EBITDA (X) |  | ROE (\%) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | FY09E | FY10E | FY09E | FY10E | FY09E | FY10E | FY09E | FY10E |
| Asian Paints | 769 | Neutral | 934 | 21.5 | 39.1 | 46.7 | 19.7 | 16.5 | 11.9 | 9.6 | 31.5 | 31.3 |
| Britannia Industries | 1,381 | Buy | 1,782 | 29.0 | 91.3 | 118.8 | 15.1 | 11.6 | 10.7 | 7.9 | 24.0 | 25.7 |
| Colgate | 417 | Buy | 451 | 8.1 | 20.3 | 23.7 | 20.5 | 17.6 | 21.5 | 18.3 | 154.2 | 149.5 |
| Dabur | 88 | Neutral | 93 | 6.0 | 4.4 | 5.2 | 20.1 | 17.0 | 16.6 | 13.0 | 44.9 | 41.3 |
| Glaxo Smithkline* | 600 | Buy | 809 | 34.8 | 44.8 | 53.9 | 13.4 | 11.1 | 8.9 | 7.1 | 25.5 | 25.9 |
| Godrej Consumer | 130 | Buy | 140 | 8.1 | 6.2 | 8.3 | 20.9 | 15.7 | 16.2 | 12.0 | 27.5 | 33.5 |
| Hind. Unilever\# | 264 | Neutral | 246 | -6.8 | 11.3 | 11.2 | 23.3 | 23.6 | 20.0 | 19.8 | 128.1 | 100.3 |
| ITC | 181 | Buy | 210 | 16.0 | 8.7 | 10.2 | 20.8 | 17.8 | 13.0 | 11.2 | 23.9 | 24.3 |
| Marico | 58 | Buy | 64 | 10.9 | 3.0 | 3.6 | 19.3 | 16.2 | 12.9 | 10.7 | 41.0 | 35.3 |
| Nestle* | 1,480 | Buy | 1,793 | 21.2 | 56.4 | 71.7 | 26.3 | 20.6 | 17.0 | 13.3 | 119.3 | 118.2 |
| Tata Tea | 563 | Neutral | 666 | 18.3 | 50.9 | 66.6 | 11.1 | 8.5 | 4.1 | 3.2 | 8.1 | 10.0 |
| United Spirits | 560 | Buy | 950 | 69.6 | 33.7 | 47.5 | 16.6 | 11.8 | 9.9 | 8.2 | 12.7 | 15.1 |

## Asian Paints

| STOCK INFO. | BLOOMBERG <br> BSE Sensex: 9,149 |
| :--- | ---: |
|  | APNT IN <br> REUTERS CODE |
| S\&P CNX: 2,784 | ASPN.BO |

3 February 2009

| Previous Recommendation: Buy | Rs769 |
| :--- | ---: |


| YEAR | NET SALES | Adj.PAT | EPS | EPS | P/E | P/BV | ROE | ROCE | EV/ | EV/ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| END | (RS M) | (RS M) | (RS) | GROWTH (\%) | (X) | (X) | (\%) | (\%) | SALES | EBITDA |
| 3/07A | 36,700 | 2,864 | 29.9 | 30.1 | 25.8 | 9.5 | 36.8 | 49.2 | 2.0 | 15.4 |
| 3/08A | 44,043 | 4,175 | 43.5 | 45.8 | 17.7 | 7.5 | 42.5 | 57.6 | 1.6 | 11.0 |
| 3/09E | 53,086 | 3,747 | 39.1 | -10.2 | 19.7 | 6.2 | 31.5 | 47.4 | 1.4 | 11.8 |
| 3/10E | 56,445 | 4,480 | 46.7 | 19.6 | 16.5 | 5.2 | 31.3 | 48.2 | 1.3 | 9.5 |

## 3QFY09 - Below expectation

\& Net Sales increased $12 \%$ YoY as volumes were flat. Poor Diwali sales pushed up dealer inventory and subsequent de-stocking led to lower volume growth.
\& Gross margin declined 520bp due to sharp increase in prices of titanium dioxide, high cost crude based inventory and forward cover of key raw materials at higher prices.

* The company has affected $\sim 7 \%$ price cut during the quarter to stimulate the slackening demand.
* International operations grew ~20\% YoY in 3QFY09, with sustained demand from Middle East (up ~40\%) and South Asia.


## Outlook

\& The management has given a cautious outlook on demand going forward. Worsening credit situation can impact Asian Paints on both counts - fresh painting (slowing real estate and construction activity) as well as repainting activity (being a discretionary spend).
8. 4QFY09 margins will be under pressure as high cost inventory will last till mid of February. However, margin pressures are expected to subside as prices of crude-linked inputs decline.

* We are lowering volume growth estimates for FY09 from $13.5 \%$ to $11 \%$ and from $15 \%$ to $9 \%$ for FY 10 due to lower discretionary spend. FY09 and FY10 EPS of Asian Paints have been revised downwards by $22 \%$ and $27 \%$ due to uncertain demand outlook and sustained pressure on margins for next 2-3 quarters. The stock trades at 19.7x FY09E and 16.5 x FY10E. Downgrade to Neutral.

| QUARTERLY PERFORMANCE |  |  |  |  |  |  |  |  | (Rs Million) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/EMARCH | FY08 |  |  |  | FY09 |  |  |  | FY08 | FYO9E |
|  | 10 | 2 Q | 3 Q | 4 Q | 10 | 2Q | 3 Q | 4QE |  |  |
| Net Sales | 9,605 | 11,332 | 11,776 | 11,330 | 12,420 | 14,753 | 13,210 | 12,703 | 44,043 | 53,086 |
| Change (\%) | 23.6 | 13.5 | 25.9 | 18.2 | 29.3 | 30.2 | 12.2 | 12.1 | 20.0 | 20.5 |
| Total Expenditure | 8,251 | 9,516 | 9,921 | 9,773 | 10,698 | 12,665 | 12,117 | 11,316 | 37,461 | 46,795 |
| EBITDA | 1,354 | 1,816 | 1,856 | 1,557 | 1,722 | 2,088 | 1,093 | 1,388 | 6,582 | 6,291 |
| Margin (\%) | 14.1 | 16.0 | 15.8 | 13.7 | 13.9 | 14.2 | 8.3 | 10.9 | 14.9 | 11.9 |
| Change (\%) | 30.8 | 35.3 | 50.3 | 33.1 | 27.2 | 15.0 | -41.1 | -10.9 | 37.7 | -4.4 |
| Interest | 49 | 69 | 54 | 39 | 55 | 68 | 66 | 27 | 212 | 216 |
| Depreciation | 141 | 146 | 150 | 154 | 154 | 186 | 202 | 173 | 592 | 716 |
| Other Income | 89 | 265 | 132 | 134 | 103 | 179 | 122 | 130 | 620 | 534 |
| Operational PBT | 1,252 | 1,866 | 1,783 | 1,497 | 1,616 | 2,014 | 946 | 1,318 | 6,399 | 5,893 |
| Non Recurring Income | 4 | -67 | -1 | -21 | -6 | -9 | -6 | 151 | -84 | 131 |
| PBT | 1,256 | 1,798 | 1,783 | 1,476 | 1,610 | 2,005 | 940 | 1,469 | 6,314 | 6,024 |
| Tax | 422 | 597 | 537 | 477 | 519 | 634 | 291 | 471 | 2,034 | 1,915 |
| Effective Tax Rate (\%) | 33.6 | 33.2 | 30.1 | 32.3 | 32.2 | 31.6 | 30.9 | 32.1 | 32.2 | 31.8 |
| PAT | 834 | 1,202 | 1,246 | 999 | 1,091 | 1,370 | 650 | 998 | 4,281 | 4,109 |
| Minorrity Interest | 15 | 63 | 58 | 54 | 29 | 55 | 60 | 87 | 189 | 230 |
| Adjusted PAT | 815 | 1,206 | 1,189 | 966 | 1,068 | 1,324 | 596 | 760 | 4,176 | 3,747 |
| Change (\%) | 34.8 | 45.1 | 66.9 | 57.2 | 31.0 | 9.8 | -49.8 | -21.4 | 45.7 | -10.3 |

E:MOSL Estimates

# Britannia Industries 

| STOCK INFO.  <br> BSE Sensex: 9,149 BLOOMBERG <br> BRIT IN <br> REUTERS CODE <br> S\&P CNX: 2,784 BRIT.BO |  |
| :--- | :--- |
| Equity Shares (m) | 23.9 |
| 52-Week Range | $1,650 / 991$ |
| 1,6,12 Rel. Perf. (\%) | $12 / 39 / 44$ |
| M.Cap. (Rs b) | 33.0 |
| M.Cap. (US\$ b) | 0.7 |


| 3 February 2009 Buy |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Previous Recommendation: Buy |  |  |  |  |  |  |  |  |  | Rs1,382 |
| YEAR | NET SALES | PAT | EPS | EPS | $\mathrm{P} / \mathrm{E}$ | P/B V | ROE | ROCE | EV/ | EV/ |
|  |  |  |  |  |  |  |  |  |  |  |
| 03/07A | 21,993 | 1,076 | 47.6 | -22.2 | 29.0 | 5.4 | 18.5 | 18.7 | 1.3 | 23.1 |
| 03/08A | 25,848 | 1,911 | 84.5 | 77.4 | 16.3 | 4.4 | 26.7 | 27.2 | 1.2 | 12.9 |
| 03/09E | 31,567 | 2,151 | 91.3 | 8.1 | 15.1 | 3.7 | 24.0 | 27.1 | 0.9 | 10.5 |
| 03/10E | 35,816 | 2,798 | 118.8 | 30.1 | 11.6 | 3.0 | 25.7 | 30.0 | 0.7 | 7.7 |

## 3QFY09 - In line

e Net sales grew $24.7 \%$ YoY on the back of high single digit volume growth and improved realization.
es Gross margin declined 330 bp as the price hikes taken were insufficient to ward off the impact of rising input cost. Major inputs like wheat and sugar have witnessed sharp increase leading to heightened margin pressures for Britannia.
E EBITDA margin decline was arrested to 80 bp as cost control initiatives in ad spend (120bp), staff cost (50bp) and other expenditure ( 50 bp ) helped arrest the decline.
\& Adj PAT grew 7.7\% YoY to Rs526m.

## Outlook

\& We expect raw material pressure to sustain on account of increase in prices of wheat and sugar, though decline in prices of packaging material and vegetable oil would provide solace.
\& The company trades at 15.1 x FY09E EPS of Rs91.3 and 11.6x FY10E EPS of Rs118.8. Resolution of management disputes and increase in payout ratio could re-rate the stock. Maintain Buy.

| QUARTERLY PERFORMANCE |  |  |  |  |  |  |  |  | (Rs Million) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/EMARCH | FY08 |  |  |  | FYO9 |  |  |  | FY08 | FY09E |
|  | $1 Q$ | 2 Q | 3 Q | 4 Q | 10 | 2 Q | 30 | 4QE |  |  |
| Net Sales | 5,769 | 6,588 | 6,564 | 6,928 | 6,933 | 8,385 | 8,183 | 8,066 | 25,848 | 31,567 |
| YoY Change (\%) | 19.5 | 19.8 | 15.7 | 15.6 | 20.2 | 27.3 | $24.7{ }^{\text {F }}$ | 16.4 | 17.5 | 22.1 |
| Total Exp | 5,323 | 5,902 | 5,976 | 6,342 | 6,357 | 7,715 | 7,527 | 7,267 | 23,530 | 28,865 |
| EBITDA | 446 | 686 | 588 | 586 | 576 | 671 | 656 | 799 | 2,318 | 2,702 |
| Margins (\%) | 7.7 | 10.4 | 9.0 | 8.5 | 8.3 | 8.0 | 8.0 | 9.9 | 9.0 | 8.6 |
| Depreciation | 69 | 72 | 73 | 77 | 79 | 82 | 86 | 91 | 291 | 337 |
| Interest | 5 | 29 | 30 | 14 | 35 | 44 | 30 | 17 | 97 | 126 |
| Other Income | 108 | 58 | 63 | 266 | 79 | 167 | 73 | 39 | 502 | 359 |
| PBT | 480 | 643 | 548 | 761 | 541 | 712 | 614 | 731 | 2,432 | 2,598 |
| Tax | 88 | 127 | 60 | 138 | 83 | 116 | 88 | 160 | 413 | 447 |
| Rate (\%) | 18.3 | 19.8 | 10.9 | 18.1 | 15.3 | 16.2 | 14.3 | 21.9 | 17.0 | 17.2 |
| PAT | 392 | 516 | 488 | 623 | 458 | 597 | 526 | 570 | 2,019 | 2,151 |
| YoY Change (\%) | 20.2 | 116.8 | 142.8 | 70.2 | 16.8 | 15.6 | 7.7 | -8.5 | 18.4 | 6.5 |
| Extraordinary Expenses | -31 | -31 | -34 | -13 | -55 | -64 | -64 | 44 | -109 | -139 |
| Reported PAT | 361 | 485 | 454 | 610 | 403 | 533 | 462 | 615 | 1,911 | 2,012 |

E:MOSL Estimates

# Colgate Palmolive 

| STOCK INFO. |
| :--- | :--- |
| BSE Sensex: 9,149 | | BLOOMBERG |
| :--- |
| CLGT IN |
| REUTERS CODE |
| S\&P CNX: 2,784 |
| COLG.BO |,


| 3 February 2009 |  |  |  |  |  |  |  |  |  | Buy <br> Rs417 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Previous Recommendation: Buy |  |  |  |  |  |  |  |  |  |  |
| year | net sales | PAT | EPS | EPS | P/E | $\mathrm{P} / \mathrm{BV}$ | roe | roce | Ev/ | Ev/ |
| End | (RS M) | (RS M) | (RS) | GROWTH (\%) | ( X ) | (X) | (\%) | (\%) | SALES | ebitda |
| 03/07A | 12,951 | 1,518 | 11.2 | 16.1 | 37.3 | 160.9 | 55.0 | 54.5 | 3.3 | 28.3 |
| 03/08A | 14,734 | 2,318 | 17.0 | 52.7 | 24.5 | 34.9 | 104.6 | 103.3 | 3.7 | 24.2 |
| 03/09E | 16,865 | 2,764 | 20.3 | 19.3 | 20.5 | 28.9 | 154.2 | 151.6 | 3.2 | 21.6 |
| 03/10E | 19,210 | 3,227 | 23.7 | 16.8 | 17.6 | 24.1 | 149.5 | 147.5 | 2.8 | 18.3 |

## 3QFY09 - Above expectation

\& Volume growth was robust with toothpaste reporting $14 \%$ volume growth YoY.
\& The company maintained its leadership in oral care with market share gains across categories. Market share in toothpaste increased 120 bp to $49.6 \%$ (January-December 2008). In toothbrush category, the company increased market share by $2.8 \%$ to $38 \%$. Market share in toothpowder also continued its uptick on the back of encouraging response to Colgate Lal Dant manjan.
\& Colgate's gross margin contracted 380bp due to high input costs on account of increase in prices of sorbitol oil and calcium carbonate. However, lower ad spend (620bp) as well as staff cost (80bp) enabled EBITDA margin expansion of 120 bp to $17.8 \%$ (est. $17.1 \%$ ).

## Outlook

2. Strong volume growth in the inflationary environment is a positive. Launch of Red Toothpowder has helped report growth in toothpowder as well, although toothpaste market is already witnessing some down trading.
\& We have an EPS forecast of Rs20.3 for FY09 and Rs23.7 for FY10. The stock trades at 20.5x FY09E and 17.6x FY10E with dividend yield of $4.3 \%$. Maintain Buy.

| QUARTERLY PERFORMANCE |  |  |  |  |  |  |  |  | (Rs Million) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/EMARCH | FY08 |  |  |  | FY09 |  |  |  | FY08 | FY09E |
|  | 10 | 2 Q | $3 Q$ | 4 Q | 10 | 2 Q | 30 | 4QE |  |  |
| Net Sales | 3,507 | 3,639 | 3,675 | 3,913 | 4,076 | 4,125 | 4,192 | 4,471 | 14,734 | 16,865 |
| YoY Change (\%) | 13.3 | 13.7 | 14.0 | 14.0 | 16.2 | 13.4 | 14.1 | 14.3 | 13.8 | 14.5 |
| Total Exp | 2,892 | 3,074 | 3,064 | 3,408 | 3,415 | 3,614 | 3,447 | 3,861 | 12,448 | 14,336 |
| EBITDA | 614 | 564 | 611 | 506 | 661 | 512 | 746 | 611 | 2,286 | 2,529 |
| Margins (\%) | 17.5 | 15.5 | 16.6 | 12.9 | 16.2 | 12.4 | 17.8 | 13.7 | 15.5 | 15.0 |
| Depreciation | 44 | 49 | 51 | 55 | 55 | 56 | 55 | 57 | 198 | 223 |
| Interest | 3 | 6 | 2 | 3.6 | 4 | 5 | 1 | 10 | 14 | 20 |
| Other Income | 210 | 196 | 228 | 214 | 312 | 270 | 228 | 215 | 848 | 1,024 |
| PBT | 777 | 705 | 787 | 662 | 913 | 721 | 918 | 758 | 2,921 | 3,310 |
| Tax | 158 | 158 | 182 | 105 | 194 | 86 | 140 | 126 | 603 | 546 |
| Rate (\%) | 20.3 | 22.4 | 23.2 | 15.9 | 21.3 | 11.9 | 15.3 | 16.6 | 20.7 | 16.5 |
| Adjusted PAT | 619 | 547 | 605 | 556 | 719 | 635 | 777 | 632 | 2,318 | 2,764 |
| YoY Change (\%) | 71.6 | 8.3 | 20.1 | 11.6 | 16.2 | 16.0 | 28.6 | 13.7 | 52.7 | 19.3 |
| Reported PAT | 609 | 547 | 605 | 556 | 719 | 635 | 777 | 632 | 2,318 | 2,764 |
| YoY Change (\%) | 68.8 | 136.2 | 20.1 | 9.9 | 18.1 | 16.0 | 28.6 | 13.7 | 44.6 | 19.3 |

$\bar{E}$ :MOSL Estimates

| STOCK INFO. <br> BSE Sensex: 9,149 | BLOOMBERG <br> DABUR IN <br> REUTERS CODE |
| :--- | ---: |
| S\&P CNX: 2,784 | DABU.BO |, | Equity Shares (m) | 864.0 |
| :--- | ---: |
| 52-Week Range | $115 / 60$ |
| 1,6,12 Rel. Perf. (\%) | $12 / 35 / 39$ |
| M.Cap. (Rs b) | 76.0 |
| M.Cap. (US\$ b) | 1.6 |


| 3 February 2009 |  |  |  |  |  |  |  |  | Neutral |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Previous Recommendation: Neutral |  |  |  |  |  |  |  |  |  | Rs88 |
| year | net sales | PAT | EPS | EPS | P/E | P/BV | RoE | ROCE | Ev/ | Ev/ |
| End | (RS M) | (RS M) | (RS) | GROWTH (\%) | (X) | (X) | (\%) | (\%) | SaLES | ebitda |
| 03/07A | 20,431 | 2,269 | 3.3 | 24.5 | 26.8 | 15.8 | 58.8 | 52.0 | 3.7 | 21.8 |
| 03/08A | 23,610 | 3,337 | 3.9 | 17.7 | 22.8 | 12.3 | 54.0 | 55.6 | 3.1 | 18.1 |
| 03/09E | 27,969 | 3,779 | 4.4 | 13.3 | 20.1 | 9.0 | 44.9 | 47.8 | 2.7 | 16.8 |
| 03/10E | 32,683 | 4,478 | 5.2 | 18.5 | 17.0 | 7.0 | 41.3 | 45.9 | 2.3 | 13.2 |

## 3QFY09 - In line

\& Dabur reported volume growth of $14.5 \%$ in 3QFY09, sustaining volume growth in challenging environment. Consumer Care division grew by $14.4 \%$ while Consumer Health Care posted a $17.7 \%$ growth during the quarter. The international business group reported sustained growth momentum, with GCC and Egypt growing at $47 \%$ and $85 \%$.
\& During 9MFY09, Chyawanprash grew by $9.2 \%$ YoY, while the Hair Oil portfolio reported growth of $19.7 \%$. Oral care continued to drag growth rates, with $3.7 \%$ YoY growth during 9 MFY 09 . Babool has failed to make much headway despite change in price value equation as it grew by just $3.6 \%$.
\& Gross margin declined 440bp due to higher input cost, especially Hydrocarbon, Honey, Sugar and Copra. However, lower ad spend (190bp) and other expenditure (110bp) helped arrest EBITDA margin decline to 130bp.

* Retail venture newU continued to pressurize the overall profitabiity of the firm with 9MFY09 losses being $\sim$ Rs 158 m . Adjusted for retail losses, EBITDA margin is flat ( 6 bp decline) with consolidated PAT growth being 17.7\%.


## Outlook

25 We are positive on the core business of Dabur under the Herbal platform. Management indicated that major growth drivers in near term would be sustained momentum in rural India as well as strong growth in international business (led by marked presence in new countries and categories).
\& EBITDA margin would remain under pressure as we believe newU would have a long gestation period and would continue to impact profitability.
\& We expect gross margin to improve 70bp in FY10, which would provide $18 \%$ PAT growth. The stock trades at 20.1x FY09E of Rs4.4 and 17x FY10E of Rs5.2. Maintain Neutral.

| QUARTERLY PERFORMANCE |  |  |  |  |  |  |  |  | (Rs Million) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/EMARCH | FY08 |  |  |  | FY09 |  |  |  | FY08 | FYO9 |
|  | 10 | 20 | 30 | 40 | 10 | 20 | 30 | 4QE |  |  |
| Net Sales | 5,208 | 5,841 | 6,497 | 6,065 | 6,040 | 6,912 | 7,787 | 7,231 | 23,610 | 27,969 |
| YoY Change (\%) | 33.0 | 5.4 | 14.7 | 14.3 | 16.0 | 18.3 | 19.9 | 19.2 | 15.6 | 18.5 |
| Total Exp | 4,416 | 4,682 | 5,334 | 5,087 | 5,168 | 5,664 | 6,497 | 6,123 | 19,517 | 23,452 |
| EBITDA | 792 | 1,160 | 1,163 | 978 | 871 | 1,248 | 1,290 | 1,108 | 4,093 | 4,517 |
| Margins (\%) | 15.2 | 19.9 | 17.9 | 16.1 | 14.4 | 18.1 | 16.6 | 15.3 | 17.3 | 16.1 |
| Depreciation | 102 | 98 | 105 | 117 | 117 | 123 | 109 | 124 | 421 | 473 |
| Interest | 47 | 42 | 44 | 35 | 40 | 40 | 69 | 29 | 168 | 178 |
| Other Income | 77 | 76 | 49 | 138 | 120 | 145 | 114 | 119 | 340 | 498 |
| PBT | 721 | 1,096 | 1,064 | 964 | 834 | 1,230 | 1,226 | 1,074 | 3,844 | 4,364 |
| Tax | 100 | 139 | 139 | 131 | 127 | 156 | 152 | 154 | 507 | 589 |
| Rate (\%) | 13.9 | 12.7 | 13.0 | 13.6 | 15.2 | 12.7 | 12.4 | 14.4 | 13.2 | 13.5 |
| Minority Interest | -1 | -8 | -20 | 29 | 1 | -4 | -11 | 10 | -1 | -4 |
| Adjusted PAT | 622 | 966 | 945 | 804 | 707 | 1,078 | 1,085 | 910 | 3,337 | 3,779 |
| YoY Change (\%) | 29.0 | 29.6 | 19.2 | 4.5 | 13.5 | 11.6 | 14.8 | 13.1 | 17.9 | 13.3 |
| Extraordinary Inc/(Exp) | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 10 | 10 | 10 |
| Reported PAT | 622 | 966 | 945 | 796 | 707 | 1,078 | 1,085 | 900 | 3,327 | 3,769 |

E:MOSL Estimates

# GlaxoSmithKline Consumer 

| STOCK INFO. <br> BSE Sensex: 9,149 | BLOOMBERG SKB IN |
| :---: | :---: |
| S\&P CNX: 2,784 | reuters code <br> GLSM.BO |
| Equity Shares (m) | 42.1 |
| 52-Week Range (Rs) | Rs) 766/480 |
| 1,6,12 Rel. Perf. (\%) | \%) 16/32/45 |
| M.Cap. (Rs b) | 25.3 |
| M.Cap. (US\$ b) | 0.5 |


| 3 February 2009 Buy |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Previous Recommendation: Buy |  |  |  |  |  |  |  |  |  | Rs600 |
| $\begin{aligned} & \text { YEAR } \\ & \text { END } \\ & \hline \end{aligned}$ | NET SALES (RS M) | $\begin{gathered} \text { PAT } \\ \text { (RS M) } \end{gathered}$ | $\begin{aligned} & \mathrm{EPS} \\ & \text { (RS) } \\ & \hline \end{aligned}$ | $\begin{gathered} \text { EPS } \\ \text { GROWTH (\%) } \end{gathered}$ | $\begin{array}{r} \mathrm{P} / \mathrm{E} \\ (\mathrm{X}) \\ \hline \end{array}$ | $\begin{gathered} \mathrm{P} / \mathrm{BV} \mathrm{n} \\ (\mathrm{X}) \\ \hline \end{gathered}$ | ROE <br> (\%) | ROCE <br> (\%) | $\begin{gathered} \text { EV/ } \\ \text { SALES } \end{gathered}$ | $\begin{gathered} \text { EV/ } \\ \text { EBITDA } \end{gathered}$ |
| 12/06A | 11,079 | 1,270 | 30.2 | 19.5 | 19.9 | 4.6 | 23.4 | 35.8 | 2.0 | 12.2 |
| 12/07A | 12,778 | 1,626 | 38.7 | 28.1 | 15.5 | 3.9 | 25.2 | 38.6 | 1.7 | 9.5 |
| 12/08E | 15,428 | 1,884 | 44.8 | 15.8 | 13.4 | 3.4 | 25.5 | 39.5 | 1.4 | 8.8 |
| 12/09E | 17,833 | 2,267 | 53.9 | 20.4 | 11.1 | 2.9 | 25.9 | 39.8 | 1.2 | 6.9 |

## 4QCY09 - Above expectation

\& Net sales growth of $17 \%$ YoY comprised $13 \%$ volume growth and $4 \%$ realization growth. Horlicks volume grew $13 \%$ ( $16 \%$ in 3QCY08) in 4Q, while Boost reported volume growth of $10 \%$ YoY ( $6 \%$ in 3QCY08). This was highest ever volume growth during fourth quarter.
\& Gross margin declined 50bp YoY due to the sustained increase prices of select inputs like liquid milk (up 10-15\%), sugar and malted barley.
es The company has launched Activ Grow targeting infant/kids in the age group of 2-5 years. The management has indicated launch of variants of Horlicks under value for money segment.

## Outlook

\& Management has indicated new launches which will increase the ad spends by 140bp in CY09.
\& GSK has undertaken $5.5 \%$ average price increase effective Jan1,2009 which will enable 140bp increase in gross margins and 120bp increase in EBIDTA margins in CY09.
\& We estimate 20.4\% PAT growth in CY09 (19\% PAT CAGR from last 5 years). We are revising CY09 EPS estimates from Rs52.9 to Rs53.9. The stock trades at 13.4x CY08E EPS of Rs44.8 and 11.1x CY09E EPS of Rs53.9. We maintain Buy.

| QUARTERLY PERFORMANCE |  |  |  |  |  |  |  |  |  | (Rs Million) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/E DECEMBER | CY07 |  |  |  | CY08 |  |  |  | CY07 | CY08 |
|  | 10 | 2 Q | 3Q | 4 Q | $1 Q$ | 2 Q | 3 Q | 4 Q |  |  |
| Net Sales | 3,265 | 3,156 | 3,516 | 2,841 | 4,106 | 3,764 | 4,225 | 3,334 | 12,778 | 15,428 |
| YoY Change (\%) | 17.9 | 17.8 | 16.6 | 7.3 | 25.8 | 19.3 | 20.2 | 17.3 | 14.9 | 20.7 |
| Total Exp | 2,641 | 2,571 | 2,839 | 2,484 | 3,309 | 3,218 | 3,594 | 2,932 | 10,535 | 13,052 |
| EBITDA | 624 | 585 | 677 | 357 | 797 | 546 | 631 | 402 | 2,243 | 2,376 |
| Margins (\%) | 19.1 | 18.5 | 19.3 | 12.6 | 19.4 | 14.5 | 14.9 | 12.1 | 17.6 | 15.4 |
| Depreciation | 108 | 109 | 111 | 108 | 106 | 102 | 104 | 107 | 435 | 419 |
| Interest | 11 | 11 | 12 | 12 | 13 | 13 | 14 | 30 | 46 | 70 |
| Other Income | 139 | 166 | 209 | 175 | 186 | 262 | 265 | 242 | 689 | 955 |
| PBT | 644 | 631 | 763 | 412 | 864 | 692 | 778 | 507 | 2,451 | 2,841 |
| Tax | 221 | 208 | 258 | 137 | 298 | 231 | 247 | 181 | 824 | 957 |
| Rate (\%) | 34.3 | 33.0 | 33.8 | 33.3 | 34.0 | 33.3 | 33.0 | 35.8 | 33.6 | 33.7 |
| PAT | 423 | 423 | 505 | 275 | 566 | 462 | 530 | 326 | 1,626 | 1,884 |
| YoY Change (\%) | 22.8 | 36.8 | 39.4 | 9.1 | 33.8 | 9.1 | 5.0 | 18.5 | 28.4 | 15.8 |

[^0]
# Godrej Consumer Products 

| STOCK INFO. |  |
| :--- | :--- |
| BSE Sensex: 9,149 | BLOOMBERG <br> GCPL IN |
| S\&P CNX: 2,784 | REUTERS CODE |
| Equity Shares (m) | 258.1 |
| 52-Week Range | $146 / 94$ |
| 1,6,12 Rel. Perf. (\%) | $0 / 46 / 66$ |
| M.Cap. (Rs b) | 33.6 |
| M.Cap. (US\$ b) | 0.7 |


| 3 February 2009 |  |  |  |  |  |  |  |  |  | $\begin{array}{r} \text { Buy } \\ \text { Rs130 } \end{array}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Previous Recommendation: Buy |  |  |  |  |  |  |  |  |  |  |
| $\begin{aligned} & \text { YEAR } \\ & \text { END } \\ & \hline \end{aligned}$ | NET SALES <br> (RS M) | $\begin{gathered} \text { PAT } \\ \text { (RS M) } \\ \hline \end{gathered}$ | $\begin{aligned} & \mathrm{EPS} \\ & \text { (RS) } \\ & \hline \end{aligned}$ | $\begin{gathered} \text { EPS } \\ \text { 3ROWTH (\%) } \end{gathered}$ | $\begin{aligned} & \mathrm{P} / \mathrm{E} \\ & (\mathrm{X}) \end{aligned}$ | $\begin{gathered} \text { P/B } V \\ (X) \\ \hline \end{gathered}$ | $\begin{aligned} & \text { ROE } \\ & (\%) \\ & \hline \end{aligned}$ | ROCE <br> (\%) | $\begin{gathered} \text { EV/ } \\ \text { SALES } \end{gathered}$ | $\begin{aligned} & \text { EV/ } \\ & \text { EBITDA } \end{aligned}$ |
| 03/07A | 9,515 | 1,342 | 5.9 | 12.5 | 21.9 | 27.5 | 110.0 | 64.8 | 3.2 | 17.0 |
| 03/08A | 11,040 | 1,592 | 7.1 | 18.6 | 18.4 | 19.6 | 92.8 | 64.4 | 2.8 | 14.3 |
| 03/09E | 13,806 | 1,602 | 6.2 | -11.9 | 20.9 | 5.8 | 27.5 | 27.9 | 2.3 | 16.2 |
| 03/10E | 15,077 | 2,132 | 8.3 | 33.1 | 15.7 | 5.3 | 33.5 | 33.3 | 2.1 | 12.0 |

## 3QFY09 - Below expectation

\& Consolidated sales increased $25.4 \%$ to Rs3.4b, marginally higher than our estimate of Rs3.3b, on account of strong growth both in toilet soaps and hair color.
\& Toilet soap sales increased $23 \%$ on the back of strong volume growth of $19 \%$ and realization growth of $4 \%$ ( $10 \%$ volume growth and $21 \%$ value growth in 9MFY09). Management indicated higher volume growth has been on account of good response to two new launches- Cinthol Deo Musk and Godrej No1 Strawberry and Walnut.
\& Hair color division reported a $14 \%$ YoY growth for 3QFY09 to Rs570m (6\% degrowth in 2QFY09). Two initiatives in hair color have been particularly successful-1) $11 \%$ price increase in Godrej Hair Dye; 2) increased trade margin and 3) the relaunch of Godrej Expert Hair Dye.
2. Gross margin declined 1,370bp despite the fall in palm oil prices as the company had 4-5 months inventory.
\& Performance in international operations has largely been in line, though Kinky's profitability continued to disappoint.

## Outlook

2. Sustained traction in toilet soaps despite the aggressive launch of ITC's Superia is encouraging, though slower pick up in hair color and Kinky's profitability is a cause of concern.
\& The management expects margins to significantly improve in 4QFY09 as the benefit of the lower palm oil prices gets accounted. Palm oil prices have fallen by $66 \%$ from their peak and are at 2-year lows.
\& We are revising our EPS estimates for FY09 and FY10 on account of delayed accrual of the benefit of palm oil decline. Our EPS estimates stand revised to Rs6.2 (earlier Rs7.1) and Rs8.3 (earlier Rs9.3).
es The stock trades at 20.9x FY09E EPS and 15.7 x FY10E EPS. Maintain Buy.

| QUARTERLY PERFORMANCE |  |  |  |  |  |  |  |  | (Rs Million) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/EMARCH | FY08 |  |  |  | FYO9 |  |  |  | FY08 | FY09E |
|  | 10 | 2 Q | 3 Q | 4 Q | 10 | 2 Q | 3 Q | 4QE |  |  |
| Net Sales | 2,863 | 2,740 | 2,728 | 2,718 | 3,616 | 3,465 | 3,421 | 3,304 | 11,026 | 13,806 |
| YoY Change (\%) | 20.5 | 18.2 | 14.6 | 12.1 | 26.3 | 26.4 | 25.4 | 21.6 | 36.2 | 25.2 |
| Total Exp | 2,352 | 2,239 | 2,159 | 2,151 | 3,121 | 3,068 | 2,938 | 2,716 | 8,881 | 11,842 |
| EBITDA | 511 | 501 | 568 | 567 | 496 | 397 | 483 | 588 | 2,145 | 1,964 |
| Margins (\%) | 17.9 | 18.3 | 20.8 | 20.9 | 13.7 | 11.5 | 14.1 | 17.8 | 19.5 | 14.2 |
| Depreciation | 44 | 46 | 48 | 43 | 55 | 46 | 51 | 65 | 182 | 217 |
| Interest | 35 | 32 | 29 | 34 | -12 | -47 | -42 | -15 | 129 | -116 |
| Other Income | 13 | 14 | 15 | -1 | 35 | 31 | 15 | 23 | 40 | 103 |
| PBT | 445 | 437 | 506 | 489 | 487 | 428 | 489 | 562 | 1,875 | 1,966 |
| Tax | 59 | 67 | 76 | 81 | 96 | 81 | 88 | 98 | 283 | 364 |
| Rate (\%) | 13.1 | 15.2 | 15.0 | 16.6 | 19.7 | 18.9 | 18.1 | 17.5 | 15.1 | 18.5 |
| PAT | 386 | 371 | 430 | 408 | 391 | 347 | 401 | 463 | 1,592 | 1,602 |
| YoY Change (\%) | 17.7 | 19.5 | 8.7 | 32.6 | 1.2 | -6.3 | -6.9 | 13.5 | 12.5 | 0.7 |
| Reported PAT | 386 | 371 | 430 | 408 | 391 | 347 | 401 | 463 | 1,592 | 1,602 |

E: MOSL Estimates

# Hindustan Unilever 

| STOCK INFO. | BLOOMBERG <br> BSE Sensex: 9,149 <br> HUVR IN |
| :--- | :--- |
| S\&P CNX: 2,784 | REUTERS CODE |
| Equity Shares (m) | $2,177.5$ |
| 52-Week Range | $267 / 185$ |
| 1,6,12 Rel. Perf. (\%) | $15 / 50 / 76$ |
| M.Cap. (Rs b) | 574.9 |
| M.Cap. (US\$ b) | 11.8 |

3 February 2009

| Previous Recommendation: Neutral |  |  |  |  |  |  |  |  |  | $\frac{\text { Rs264 }}{\substack{\text { EV/ } \\ \text { EBITDA }}}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| YEAR END | NET SALES <br> (RS M) | $\begin{gathered} \text { PAT } \\ \text { (RS M) } \end{gathered}$ | $\begin{array}{r} \text { EPS } \\ \text { (RS) } \\ \hline \end{array}$ | EPS <br> GROWTH (\%) | $\begin{aligned} & \mathrm{P} / \mathrm{E} \\ & (\mathrm{X}) \end{aligned}$ | $\begin{gathered} \text { P/B } V \\ (\mathrm{X}) \\ \hline \end{gathered}$ | ROE <br> (\%) | ROCE <br> (\%) | $\begin{aligned} & \text { EV/ } \\ & \text { SALES } \end{aligned}$ |  |
| 12/06A | 121,034 | 15,397 | 7.0 | 17.5 | 37.8 | 21.4 | 56.5 | 67.0 | 4.6 | 33.7 |
| 12/07A | 137,178 | 17,691 | 8.1 | 16.4 | 32.5 | 39.9 | 122.9 | 144.7 | 4.1 | 29.7 |
| 03/09E | 207,133 | 24,690 | 11.3 | 39.6 | 23.3 | 29.8 | 128.1 | 154.1 | 2.6 | 20.4 |
| 03/10E | 179,561 | 24,345 | 11.2 | -1.4 | 23.6 | 23.7 | 100.3 | 121.3 | 3.0 | 20.2 |

\# Change in accounting period from December to March

## 4QCY09 - Below expectation

\& Volume growth declined QoQ to $2.3 \%$ ( $6.8 \%$ in 3QCY08). This has been the third consecutive fall from the double digit volume growth reported in 1QCY08 (10.4\%).
\& YoY market share declined in all key categories: toilet soaps (470bp), shampoo (180bp), skin creams (280bp). Detergents, however, reported 90bp improvement in market share.
\& Soaps and detergent reported a $25 \%$ revenue growth while personal products reported muted growth of $11 \%$. Beverages grew $24 \%$, while exports declined $23 \%$ YoY.
\& Gross margins have declined 230bp while EBIDTA margin increased by 80 bp YoY due to 140 bp decline in other expenses and 160 bp lower advertising spend.

## Outlook

\& Rising inflation and pressure on consumer's wallet can lower volume growth in the coming quarters. We believe the threat from smaller players/unorganized players could be significant going forward.

* Declining market share in toilet soaps (4-5\% volume growth) doesn't augur well as this segment contribute $24 \%$ to the sales and $33 \%$ to EBIT of HUL.
\& Our FY09 EPS estimate stands at Rs11.3 and FY10 EPS estimate to Rs11.2. The stock trades at 23.3x FY09 and 23.6x FY10. Maintain Neutral.

| QUARTERLY PERFORMANCE |  |  |  |  |  |  |  |  |  | s Million) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/E DECEMBER | Y07 |  |  |  | FY09 |  |  |  |  | CY08 | FY09 |
|  | 10 | 20 | 30 | 4 Q | 10 | $2 Q$ | $3 Q$ | 4 Q | 50 |  |  |
| Net Sales (incl service inc) | 31,843 | 34,814 | 33,646 | 36,874 | 37,939 | 42,157 | 40,279 | 43,077 | 43,681 | 163,452 | 207,133 |
| YoY Change (\%) | 13.8 | 12.9 | 9.7 | 16.8 | 19.1 | 21.1 | 19.7 | 16.8 | 15.1 | 19.2 | 51.0 |
| Total Expenditure | 28,224 | 29,801 | 29,170 | 31,232 | 33,861 | 36,642 | 35,516 | 36,147 | 38,124 | 142,165 | 180,289 |
| EBITDA | 3,620 | 5,013 | 4,476 | 5,642 | 4,078 | 5,515 | 4,763 | 6,931 | 5,557 | 21,287 | 26,844 |
| YoY Change (\%) | 9.5 | 20.9 | 11.1 | 12.8 | 12.7 | 10.0 | 6.4 | 22.8 | 36.3 | 12.9 | 42.4 |
| Margins (\%) | 11.4 | 14.4 | 13.3 | 15.3 | 10.7 | 13.1 | 11.8 | 16.1 | 12.7 | 13.0 | 13.0 |
| Depreciation | 329 | 333 | 353 | 369 | 363 | 379 | 393 | 406 | 412 | 1,541 | 1,952 |
| Interest | 51 | 110 | 68 | 26 | 35 | 87 | 0 | 0 | 0 | 122 | 0 |
| Other Income | 908 | 1,058 | 1,059 | 1,597 | 1,009 | 1,647 | 1,239 | 1,001 | 1,028 | 4,896 | 5,924 |
| PBT | 4,147 | 5,628 | 5,114 | 6,844 | 4,689 | 6,695 | 5,610 | 7,526 | 6,296 | 24,520 | 30,816 |
| Tax | 809 | 1,111 | 1,021 | 1,305 | 905 | 1,294 | 1,231 | 1,425 | 1,272 | 4,854 | 6,126 |
| Rate (\%) | 19.5 | 19.7 | 20.0 | 19.1 | 19.3 | 19.3 | 21.9 | 18.9 | 20.2 | 19.8 | 19.9 |
| Adjusted PAT | 3,339 | 4,517 | 4,093 | 5,540 | 3,784 | 5,401 | 4,379 | 6,101 | 5,024 | 19,666 | 24,690 |
| Yo Y Change (\%) | 13.6 | 19.1 | 6.9 | 14.6 | 13.3 | 19.6 | 7.0 | 10.1 | 32.8 | 11.2 | 39.6 |
| Extraordinary Inc/(Exp) | 590 | 414 | -12 | 775 | 25 | 180 | 1,087 | 56 | 0 | 1,349 | 1,349 |
| Reported Profit | 3,929 | 4,931 | 4,081 | 6,314 | 3,810 | 5,582 | 5,466 | 6,157 | 5,024 | 21,015 | 26,039 |
| YoY Change (\%) | -11.3 | 29.6 | -21.6 | 23.5 | -3.0 | 13.2 | 34.0 | -2.5 | 31.9 | 9.1 | 35.2 |

E: MOSL Estimates

| STOCK INFO. | BLOOMBERG |
| :--- | :--- |
| BSE Sensex: 9,149 | ITC IN <br> REUTERS CODE |
| S\&P CNX: 2,784 | ITC.BO |
| Equity Shares (m) | $3,762.2$ |
| 52-Week Range | $232 / 132$ |
| 1,6,12 Rel. Perf. (\%) | $12 / 34 / 39$ |
| M.Cap. (Rs b) | 681.0 |
| M.Cap. (US\$ b) | 14.0 |


| 3 February 2009 Buy |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Previous Recommendation: Buy |  |  |  |  |  |  |  |  |  | Rs181 |
| YEAR <br> END | NET SALES (RS M) | $\begin{gathered} \text { PAT } \\ (\text { RS M) } \end{gathered}$ | $\begin{aligned} & \text { EPS } \\ & \text { (RS) } \end{aligned}$ | EPS GROWTH (\%) | $\begin{aligned} & \mathrm{P} / \mathrm{E} \\ & (\mathrm{X}) \end{aligned}$ | $\begin{gathered} \text { P/BV } \\ (X) \end{gathered}$ | ROE <br> (\%) | ROCE <br> (\%) | $\begin{gathered} \text { EV/ } \\ \text { SALES } \end{gathered}$ | $\begin{gathered} \text { EV/ } \\ \text { EBITDA } \end{gathered}$ |
| 03/07A | 121,643 | 27,000 | 7.2 | 13.2 | 25.2 | 6.5 | 25.9 | 35.4 | 5.3 | 16.2 |
| 03/08A | 139,475 | 31,201 | 8.3 | 15.6 | 21.8 | 5.6 | 25.9 | 35.8 | 4.6 | 14.7 |
| 03/09E | 159,026 | 32,748 | 8.7 | 5.0 | 20.8 | 5.0 | 23.9 | 33.7 | 4.0 | 13.2 |
| 03/10E | 180,658 | 38,264 | 10.2 | 16.8 | 17.8 | 4.3 | 24.3 | 34.7 | 3.4 | 11.4 |

## 3QFY09 - Below expectation

\& Cigarette volume declined by $3.5 \%$ ( $2 \%$ in 2QFY09) due to higher base effect in 3QFY08. PBIT margin grew by 184bp to $29.1 \%$ ( $27.8 \%$ in 2QFY09) due to full benefit of price increase.
\& New FMCG sales grew $11 \%$ YoY, while PBIT losses increased by $97 \%$ to Rs 1.27 b. ITC has attributed lower sales growth to defocus on low margin products and impact of slowdown on lifestyle retailing and impulse fast foods.
\& Hotel business degrew $14.1 \%$ as economic slowdown and terrorist attacks in Mumbai took toll on occupancy rates as well as ARR.
\& Paper \& paperboards sales grew $13.6 \%$, while PBIT degrew $6.1 \%$ as margins declined 300 bp due to increase in depreciation.

* Agri business reported $6 \%$ decline in sales to Rs6.2b due to lower volumes of soya. However, higher realization in leaf tobacco exports enabled the division to report margin expansion of 350bp.


## Outlook

\& ITC's focus seems to be shifting from topline growth to profitability. We believe cigarette and paper segments will continue to be key profit drivers in the near term. Hotels and new FMCG will remain under pressure.

* We are cutting earnings estimates to factor in higher losses in new FMCG and profit decline in hotel business.
\& Our revised estimates for FY09 and FY10 are Rs8.7 (v/s Rs9) and Rs10.2 (v/s Rs10.4) respectively. The stock trades at 20.8x FY09E EPS of Rs8.7 and 17.8x FY10E EPS of Rs10.2. Maintain Buy.

| Y/EMARCH | FY08 |  |  |  | FY09 |  |  |  | FY08 | FY09E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 10 | 2 Q | 3 Q | 4 Q | 10 | 2 Q | 3 Q | 4QE |  |  |
| Net Sales | 33,252 | 32,734 | 34,580 | 39,344 | 38,997 | 37,633 | 38,333 | 44,063 | 139,475 | 159,026 |
| YoY Change (\%) | 16.7 | 13.4 | 11.0 | 13.5 | 17.3 | 15.0 | 10.9 | 12.0 | 14.7 | 14.0 |
| Total Exp | 21,977 | 22,414 | 22,583 | 28,897 | 27,726 | 26,473 | 24,806 | 32,072 | 95,436 | 111,077 |
| EBITDA | 11,276 | 10,320 | 11,997 | 10,447 | 11,271 | 11,160 | 13,527 | 11,992 | 44,039 | 47,950 |
| Margins (\%) | 33.9 | 31.5 | 34.7 | 26.6 | 28.9 | 29.7 | 35.3 | 27.2 | 31.6 | 30.2 |
| Depreciation | 1,010 | 1,062 | 1,097 | 1,215 | 1,261 | 1,340 | 1,442 | 1,443 | 4,385 | 5,486 |
| Interest | -8 | 9 | 18 | 27 | 14 | 28 | 5 | 54 | 46 | 100 |
| Other Income | 1,016 | 2,083 | 1,374 | 1,637 | 1,144 | 2,098 | 1,229 | 1,325 | 6,109 | 5,795 |
| PBT | 11,289 | 11,331 | 12,256 | 10,842 | 11,140 | 11,890 | 13,310 | 11,819 | 45,718 | 48,159 |
| Tax | 3,461 | 3,623 | 3,948 | 3,485 | 3,653 | 3,864 | 4,277 | 3,617 | 14,517 | 15,411 |
| Rate (\%) | 30.7 | 32.0 | 32.2 | 32.1 | 32.8 | 32.5 | 32.1 | 30.6 | 31.8 | 32.0 |
| Reported PAT | 7,829 | 7,709 | 8,307 | 7,357 | 7,487 | 8,027 | 9,032 | 8,202 | 31,201 | 32,748 |
| YoY Change (\%) | 20.0 | 13.4 | 15.8 | 13.1 | -4.4 | 4.1 | 8.7 | 11.5 | 15.4 | 5.0 |
| Adjusted PAT | 7,829 | 7,709 | 8,307 | 7,357 | 7,487 | 8,027 | 9,032 | 8,202 | 31,201 | 32,748 |
| YoY Change (\%) | 20.0 | 13.4 | 15.8 | 13.1 | -4.4 | 4.1 | 8.7 | 11.5 | 15.6 | 5.0 |

E: MOSL Estimates

| STOCK INFO. |
| :--- | :--- |
| BSE Sensex: 9,149 | | BLOOMBERG |  |
| :--- | ---: |
| MRCO IN |  |
| REUTERS CODE |  |
| S\&P CNX: 2,784 | MRCO.BO |,


| 3 February 2009 |  |  |  |  |  |  |  |  |  | Buy <br> Rs58 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Previous Recommendation: Buy |  |  |  |  |  |  |  |  |  |  |
| YEAR | NET SALES | PAT | EPS | EPS | P/E | P/bv | roe | Roce | Ev/ | EV/ |
| End | (RS M) | (RS M) | (RS) | GROWTH (\%) | (X) | (X) | (\%) | (\%) | SaLES | ebitda |
| 03/07A | 15,569 | 989 | 1.6 | -10.8 | 36.1 | 18.4 | 51.4 | 36.1 | 2.4 | 18.8 |
| 03/08A | 19,067 | 1,589 | 2.6 | 60.6 | 22.5 | 11.2 | 50.5 | 33.5 | 2.0 | 15.5 |
| 03/09E | 24,410 | 1,851 | 3.0 | 16.5 | 19.3 | 7.8 | 41.0 | 34.4 | 1.5 | 12.7 |
| 03/10E | 26,115 | 2,202 | 3.6 | 19.0 | 16.2 | 5.7 | 35.3 | 37.5 | 1.4 | 10.5 |

## 3QFY09 - In line

es Consolidated net sales of Marico recorded a $23 \%$ YoY growth, largely led by price increases ( $15 \%$ ) and $7 \%$ volume growth ( $\mathrm{v} / \mathrm{s} 11 \%$ in 2QFY09 and $15 \%$ in 1QFY09). Brands in Pure Coconut Oil category - Parachute and Nihar have reported $9 \%$ volume growth while the Hair Oil volumes (in rigid packs) have increased by $15 \%$ YoY.
\& Saffola grew by a mere $3 \%$ YoY on account of the rising price differential between Saffola and other edible oils leading to slower uptrading to Saffola (Most edible oils, except Safflower Oil, have fallen in line with crude).
25 Marico witnessed margin pressure on account of higher raw material prices- Copra (up $\sim 25 \%$ ), Safflower oil (up $\sim 50 \%$ ). Gross margins for the quarter have declined 210bp.
\& Kaya Skin care has reported sales of Rs410m (59\% growth YoY). The management indicated pressure in the current environment given the high ticket discretionary spend as a result of which the same store sales growth declined to $13 \% \mathrm{v} / \mathrm{s} 26 \%$ in 2QFY09. International Business grew $44 \%$ YoY.

## Outlook

\& Volume growth in categories like Coconut oil and Hair oil is under pressure as conversion from loose oil to branded consumption could has got impacted due to price increase. Decline in Copra and Saflour oil from March could provide respite.
\& We believe future growth platform for Marico would be under the health and wellness platform under brands like Saffola and Kaya.
2. We remain positive on the company's long-term growth strategy. The stock trades at 19.3x FY09E EPS of Rs3 and 16.2x FY10E EPS of Rs3.6. We maintain Buy.

| QUARTERLY PERFORMANCE |  |  |  |  |  |  |  |  | (Rs M illion) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/EMARCH | FY08 |  |  |  | FY09 |  |  |  | FY08 | FY09E |
|  | 10 | 2 Q | 3 Q | 4 Q | 10 | 2 Q | 3 Q | 4QE |  |  |
| Net Sales | 4,691 | 4,638 | 5,062 | 4,675 | 6,009 | 6,035 | 6,228 | 6,137 | 19,067 | 24,410 |
| YoY Change (\%) | 25.8 | 22.7 | 23.7 | 17.8 | 28.1 | 30.1 | 23.0 | 31.3 | 22.5 | 28.0 |
| Total Exp | 4,031 | 3,990 | 4,420 | 4,220 | 5,253 | 5,296 | 5,437 | 5,489 | 16,603 | 21,474 |
| EBITDA | 660 | 648 | 643 | 456 | 757 | 739 | 791 | 648 | 2,464 | 2,935 |
| Margins (\%) | 14.1 | 14.0 | 12.7 | 9.7 | 12.6 | 12.2 | 12.7 | 10.6 | 12.9 | 12.0 |
| Depreciation | 58 | 64 | 66 | 79 | 75 | 82 | 98 | 92 | 309 | 346 |
| Interest | 71 | 65 | 68 | 73 | 80 | 87 | 68 | 129 | 277 | 364 |
| Other Income | 7 | 5 | 3 | 37 | 10 | 12 | 31 | 64 | 67 | 117 |
| PBT | 539 | 523 | 511 | 341 | 612 | 583 | 657 | 491 | 1,945 | 2,343 |
| Tax | 136 | 101 | 83 | 39 | 149 | 111 | 148 | 84 | 360 | 492 |
| Rate (\%) | 25.3 | 19.3 | 16.3 | 11.4 | 24.4 | 19.1 | 22.5 | 17.0 | 18.5 | 21.0 |
| Adjusted PAT | 402 | 423 | 428 | 302 | 463 | 471 | 509 | 407 | 1,586 | 1,851 |
| YoY Change (\%) | 32.9 | 38.0 | 54.4 | -2.4 | 15.1 | 11.6 | 19.0 | 35.0 | 60.4 | 16.7 |
| Exceptional Items | 0 | 0 | 31 | 106 | 0 | 0 | 0 | 0 | 106 | 0 |
| Reported PAT | 402 | 423 | 459 | 408 | 463 | 471 | 509 | 407 | 1,692 | 1,851 |

E:MOSL Estimates

| STOCK INFO. | BLOOMBERG |
| :--- | :--- |
| BSE Sensex: 9,149 | TT IN |
|  | REUTERS CODE |
| S\&P CNX: 2,784 | TTTE.BO |
| Equity Shares (m) | 61.8 |
| 52-Week Range | $936 / 430$ |
| 1,6,12 Rel. Perf. (\%) | $-2 / 15 / 21$ |
| M.Cap. (Rs b) | 34.8 |
| M.Cap. (US\$ b) | 0.7 |

3 February 2009
Previous Recommendation: Neutral Rs563

| YEAR | NET SALES | PAT | EPS | EPS | P/E | P/BV | ROE | ROCE | EV/ | EV/ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | ---: |
| END | (RS M) | (RS M) | (RS) | GROWTH (\%) | $(\mathbf{X})$ | (X) | (\%) | (\%) | SALES | EBITDA |
| 3/07A | 40,446 | 2,710 | 43.8 | -7.2 | 12.8 | 1.5 | 12.5 | 11.7 | 1.8 | 10.2 |
| 3/08E | 43,923 | 2,898 | 46.9 | 7.0 | 12.0 | 1.0 | 8.1 | 11.5 | 0.7 | 4.2 |
| 3/09E | 48,533 | 3,149 | 50.9 | 8.7 | 11.1 | 0.9 | 8.1 | 13.6 | 0.5 | 4.1 |
| 3/10E | 52,290 | 4,120 | 66.6 | 30.8 | 8.5 | 0.8 | 10.0 | 15.1 | 0.5 | 3.2 |

## 3QFY09- Below expectation

8 3QFY09 results are below estimates with consolidated net sales at Rs.13b, up 14.6\% (est. Rs12.65). EBITDA margin declined 400bp to $13.2 \%$ (est $14.6 \%$ ). Adj PAT degrew $3.3 \%$ to Rs821m (est of Rs700m). The company recorded foreign exchange gain to the tune of Rs5.8b on sterling depreciation against dollar on short term dollar investment held by Tata Tea GB.
\& Tata Tea standalone sales increased $22.8 \%$, ( $13.6 \%$ in 1HFY09) due to strong branded tea performance as well as price increases. Tata Coffee reported $20 \%$ increase in consolidated sales to Rs3b, while EBITDA margin declined 390bp to $14.4 \%$. PAT degrew $95 \%$ to Rs 4 m (Rs 79 m in 3QFY08). Mount Everest Mineral water net sales declined $12 \%$ to Rs59.9m with a net loss of Rs73.9 (up 35\% YoY).
\& Sharp increase in material cost led to gross margin contraction of 520bp, while lower ad spend helped arrest EBITDA margin decline to 400bp. EBITDA declined $12 \%$ YoY to Rs1.7b.

## Outlook

\& The management believes tea is witnessing a typical commodity boom and is at the tipping point. We believe even if tea prices retreat from current levels, margin pressures for Tata tea would continue for the coming quarter as well.
\& Tata Tea has restructured US operations due to poor demand condition and to control cost.
\& We have FY09 and FY10 EPS estimates of Rs50.9 and Rs66.6. The stock trades at 11.1x FY09 earnings and 8.5x FY10 earnings. Maintain Neutral.

| QUARTERLY PERFORMANCE (Rs Million) |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/EMARCH | FY08 |  |  |  | FY09 |  |  |  | FY08 | FY09E |
|  | $1 Q$ | 2 Q | 3 Q | 4 Q | 10 | 20 | 3 Q | 4QE |  |  |
| Net Sales | 10,107 | 10,548 | 11,849 | 11,768 | 11,347 | 12,003 | 13,009 | 12,175 | 43,923 | 48,533 |
| YoY Change (\%) | 26.5 | 8.3 | 6.5 | 1.5 | 12.3 | 13.8 | 9.8 | 3.5 | 8.6 | 10.5 |
| Total Exp | 8,502 | 8,955 | 9,643 | 10,153 | 9,809 | 10,568 | 11,286 | 10,580 | 36,821 | 42,244 |
| EBITDA | 1,606 | 1,594 | 2,112 | 1,615 | 1,538 | 1,435 | 1,722 | 1,595 | 7,102 | 6,290 |
| Margins (\%) | 15.9 | 15.1 | 17.8 | 13.7 | 13.6 | 12.0 | 13.2 | 13.1 | 16.2 | 13.0 |
| Depreciation | 236 | 217 | 227 | 235 | 222 | 221 | 241 | 239 | 916 | 923 |
| Interest | 918 | 632 | 504 | 118 | 109 | 154 | 155 | 1,733 | 2,214 | 2,150 |
| Other Income | 86 | 268 | 47 | 59 | 74 | 281 | 91 | 2,306 | 397 | 2,752 |
| PBT | 538 | 1,013 | 1,427 | 1,322 | 1,280 | 1,341 | 1,418 | 1,929 | 4,369 | 5,969 |
| Tax | 134 | 298 | 503 | 594 | 440 | 402 | 485 | 642 | 1,534 | 1,970 |
| Rate (\%) | 25.0 | 29.4 | 35.2 | 44.9 | 34.4 | 30.0 | 34.2 | 33.3 | 35.1 | 33.0 |
| PAT | 404 | 715 | 924 | 728 | 840 | 939 | 934 | 1,286 | 2,835 | 3,999 |
| YoY Change (\%) | -52.7 | -41.1 | 81.8 | 158.8 | 108.1 | 31.4 | 1.0 | 76.7 | 7.9 | 41.1 |
| Minority Interest/ Share of Associate | -50 | 132 | -103 | -46 | -97 | -117 | 113 | -749 | 63 | -850 |
| Adjusted PAT | 353 | 847 | 821 | 682 | 743 | 822 | 821 | 538 | 2,898 | 3,149 |
| YoY Change (\%) | -56.9 | -33.4 | 96.6 | 237.4 | 110.3 | -2.9 | -0.1 | -21.1 | 7.0 | 8.7 |
| Extraordinary Gains | 86 | -33 | 15,723 | 448 | 14 | 1,356 | 4,002 | 0 | 16,160 | 1,370 |
| Reported PAT | 439 | 813 | 13,073 | 1,130 | 757 | 2,178 | 4,822 | 538 | 19,059 | 4,519 |
| YoY Change (\%) | -48 | -58 | 1,016 | 123.7 | 72.4 | 167.7 | -63.1 | -52.4 | 316.1 | -76.3 |

# United Spirits 

| STOCK INFO. | BLOOMBERG |
| :--- | :--- |
| BSE Sensex: 9,149 | UNSP IN |
| REUTERS CODE |  |
| S\&P CNX: 2,784 | UNSP.BO |
| Equity Shares (m) | 100.2 |
| 52-Week Range | $1,873 / 426$ |
| 1,6,12 Rel. Perf. (\%) | $-31 /-19 /-17$ |
| M.Cap. (Rs b) | 56.1 |
| M.Cap. (US\$ b) | 1.1 |


| 3 February 2009 Buy |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Previous Recommendation: Buy |  |  |  |  |  |  |  |  |  | Rs560 |
| YEAR | NET SALES | PAT | EPS | EPS | P/E | P/BV | RoE | Roce | EV/ | EV/ |
| END | (RS M) | (RS M) | (RS) | GROWTH (\%) | (X) | (X) | (\%) | (\%) | SALES | Ebitda |
| 03/07A | 29,619 | 2,973 | 41.2 | 902.9 | 13.6 | 3.0 | 19.3 | 16.2 | 1.6 | 11.2 |
| 03/08A | 46,275 | 3,012 | 33.7 | -18.3 | 16.6 | 2.2 | 12.4 | 12.1 | 2.3 | 9.8 |
| 03/09E | 54,062 | 3,015 | 33.7 | 0.0 | 16.6 | 2.1 | 12.7 | 11.6 | 2.0 | 9.8 |
| 03/10E | 61,659 | 4,248 | 47.5 | 40.9 | 11.8 | 1.8 | 15.1 | 13.2 | 1.7 | 8.1 |

## 3QCY09 - Below expectation

\& $20 \%$ volume growth on the back of a strong $19 \%$ volume growth in first line brands. McDowell No1 grew by $17 \%$, Royal challenge grew by $13 \%$ while Antiquity and Signature posted strong $33 \%$ and $28 \%$ growth.
\& The sharp increase in key raw material like ENA and Molasses and glass resulted in a 960bp decline in gross margin to $38.9 \%$. EBITDA margin declined by 890 bp to $10.3 \%$. PAT declined by $65 \%$ YoY to Rs 306 m v/s our estimate of Rs1.06b.
\& Whyte \& Mackay reported at $8.5 \%$ growth in revenue to GBP152m for 9MFY09. While EBITDA at GBP53.9m was up $5 \%$ YoY as margins declined 168 bps .

## Outlook

es Management is confident of sustaining the volume growth traction in the coming quarters.
E EBITDA margin would bounce back by 360bp in 4QFY09 from $10.3 \%$ in 3QFY09 but it would take the company quite some time to return to normal level of profitability.
\& Debt repayment is likely to put a strain on the financials of United Spirits. Repayment obligations stand at Rs5.7b in FY10 and Rs14.5b in FY11. The management has indicated sale of treasury stock ( $17 \%$ of equity) and is open to $49 \%$ stake sale in Whyte \& Mackay, which has scotch stocks of GBP456m. However, deleveraging could be a difficult task due to sharp decline across asset classes and treasury stock value (Rs10b).
\& We are downgrading our EPS estimates from Rs46.7 to Rs33.7 for FY09 and from Rs67 and Rs 47.5 for FY10. The stock trades at $16.6 \times$ FY09E and $11.8 x$ FY10E earnings. The divestment of treasury stock to a strong strategic investor could rerate the stock significantly. We maintain Buy.

| QUARTERLY PERFORMANCE (STANDALONE) |  |  |  |  |  |  |  |  | (RS MILLION) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/EMARCH | FY08 |  |  |  | FY09 |  |  |  | FYO8 | FYO9E |
|  | 10 | 2 Q | 3 Q | 4Q | 10 | 2 Q | 3 Q | 4QE |  |  |
| Net Sales | 7,657 | 7,526 | 8,890 | 7,590 | 10,134 | 9,020 | 10,293 | 8,897 | 31,663 | 38,344 |
| YoY Change (\%) | 16.9 | 19.1 | 15.3 | 15.9 | 32.3 | 19.9 | 15.8 | 17.2 | 6.9 | 21.1 |
| Total Exp | 5,943 | 6,047 | 7,182 | 6,237 | 7,982 | 7,230 | 9,229 | 7,662 | 25,359 | 32,103 |
| EBITDA | 1,714 | 1,479 | 1,708 | 1,353 | 2,152 | 1,790 | 1,063 | 1,236 | 6,304 | 6,242 |
| Margins (\%) | 22.4 | 19.6 | 19.2 | 17.8 | 21.2 | 19.8 | 10.3 | 13.9 | 19.9 | 16.3 |
| Depreciation | 70 | 72 | 90 | 85 | 82 | 87 | 87 | 97 | 317 | 354 |
| Interest | 292 | 328 | 328 | 329 | 341 | 395 | 529 | 485 | 1,276 | 1,750 |
| PBT From operations | 1,352 | 1,079 | 1,290 | 939 | 1,729 | 1,308 | 447 | 654 | 4,711 | 4,138 |
| Other income | 49 | 112 | 96 | 107 | 72 | 125 | 60 | 226 | 294 | 483 |
| PBT | 1,400 | 1,191 | 1,386 | 1,047 | 1,801 | 1,433 | 507 | 880 | 5,004 | 4,621 |
| Tax | 505 | 389 | 505 | 396 | 630 | 494 | 201 | 318 | 1,794 | 1,643 |
| Rate (\%) | 36.0 | 32.7 | 36.4 | 37.8 | 35.0 | 34.5 | 39.7 | 36.2 | 35.8 | 35.6 |
| PAT | 896 | 802 | 882 | 651 | 1,171 | 939 | 306 | 561 | 3,211 | 2,978 |
| YoY Change (\%) | 98.5 | 42.5 | 14.7 | 14.1 | 30.8 | 17.0 | -65.3 | -13.8 | -32 | -7.3 |
| Reported PAT | 896 | 802 | 882 | 651 | 1,171 | 939 | 306 | 561 | 3,211 | 2,978 |

E: MOSL Estimates


For more copies or other information, contact
Institutional: Navin Agarwal. Retail: Manish Shah
Phone: (91-22) 39825500 Fax: (91-22) 22885038. E-mail: inquire@motilaloswal.com
Motilal Oswal Securities Ltd, 3rd Floor, Hoechst House, Nariman Point, Mumbai 400021
This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form.

The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon such. MOSt or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

MOSt and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

## Disclosure of Interest Statement

The MOSt group and its Directors own shares in the following companies covered in this report: Marico
MOSt has no broking relationships with the companies covered in this report.
MOSt is engaged in providing investment-banking services in the following companies covered in this report: Nil
This information is subject to change without any prior notice. MOSt reserves the right to make modifications and alternations to this statement as may be required from time to time. Nevertheless, MOSt is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.


[^0]:    E: MOSL Estimates

